We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · August 14, 2014

Carboplatin and/or Bevacizumab Plus Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in TNBC

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-Per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
J. Clin. Oncol 2014 Aug 04;[EPub Ahead of Print], WM Sikov, DA Berry, CM Perou, B Singh, CT Cirrincione, SM Tolaney, CS Kuzma, TJ Pluard, G Somlo, ER Port, M Golshan, JR Bellon, D Collyar, OM Hahn, LA Carey, CA Hudis, EP Winer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading